The groups spend big on Terns and Arcellx.
ApexOnco Front Page
Recent articles
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.
Syndax’s Revuforj beats Kura in NPM1-mutated AML.
The group is expanding its mRNA-4359 trial to include first-line melanoma.
FDA decisions loom for Kura’s ziftomenib and Bayer’s sevabertinib.
